Last reviewed · How we verify
Atu027 & gemcitabine in treatment arm 1
Atu027 & gemcitabine in treatment arm 1 is a Small molecule drug developed by Silence Therapeutics GmbH. It is currently in Phase 1 development.
At a glance
| Generic name | Atu027 & gemcitabine in treatment arm 1 |
|---|---|
| Sponsor | Silence Therapeutics GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atu027 & gemcitabine in treatment arm 1 CI brief — competitive landscape report
- Atu027 & gemcitabine in treatment arm 1 updates RSS · CI watch RSS
- Silence Therapeutics GmbH portfolio CI
Frequently asked questions about Atu027 & gemcitabine in treatment arm 1
What is Atu027 & gemcitabine in treatment arm 1?
Atu027 & gemcitabine in treatment arm 1 is a Small molecule drug developed by Silence Therapeutics GmbH.
Who makes Atu027 & gemcitabine in treatment arm 1?
Atu027 & gemcitabine in treatment arm 1 is developed by Silence Therapeutics GmbH (see full Silence Therapeutics GmbH pipeline at /company/silence-therapeutics-gmbh).
What development phase is Atu027 & gemcitabine in treatment arm 1 in?
Atu027 & gemcitabine in treatment arm 1 is in Phase 1.